Merck Partners With Korea’s Samsung Bioepis On Multiple Biosimilar Targets
This article was originally published in The Pink Sheet Daily
Executive Summary
Samsung Bioepis will be responsible for development, manufacturing and registration, while Merck will be responsible for commercializing any resulting drugs. Merck says the partnership will complement the firm’s internal biologics portfolio.